Targeted Disease(s):
Pulmonary Fibrosis
Purpose of Study:
The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis. To demonstrate that sarilumab treatment will be effective for inducing and maintaining glucocorticoid-free remission in male or female patients with biopsy proven active, glucocorticoid-dependent sarcoidosis affecting the lungs, lymph nodes, liver, kidneys, spleen, bone, soft tissues, skin, and/or eyes.
Study Dates:
September 5, 2019 - July 2, 2025
Study Location:
Nationwide
Lead Institution:
Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center
Contact:
Matthew Baker
541-760-8182
mbake13@stanford.edu
